FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
RALEIGH, N.C., Oct. 19, 2017 -- INC Research/inVentiv Health (Nasdaq:INCR), the only fully-integrated biopharmaceutical solutions organization combining a CRO and CCO (Contract Commercial Organization), will release its third quarter 2017 financial results on Thursday, November 9, 2017, prior to its earnings call at 8:00 a.m. EST.
Participants may access the conference call live via webcast on the Investor Relations section of the INC Research website at investor.incresearch.com. To participate via telephone, please dial +1 877 930 8058 within the United States or +1 253 336 7551 outside the United States, approximately 15 minutes prior to the scheduled start time. The conference ID for the call is 3396217.
A webcast replay will be available on the Investor Relations section of the INC Research website at investor.incresearch.com after 1:00 p.m. on November 9. In addition, an audio replay will be available for one week following the call and will be accessible by dialing +1 855 859 2056 within the United States or +1 404 537 3406 outside the United States. The replay ID is 3396217.
About INC Research/inVentiv Health
INC Research/inVentiv Health (Nasdaq:INCR) is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to address new market realities where clinical and commercial share expertise, data and insights to accelerate biopharmaceutical performance. With more than 22,000 employees and the ability to support customers in more than 110 countries, our global scale and deep therapeutic alignment enables INC Research/inVentiv Health to help customers successfully navigate an increasingly complex environment. For more information on our Raleigh, N.C.-based company, visit incresearch.com or inventivhealth.com.
Investor Relations Contact:
Ronnie Speight
Vice President, Investor Relations
+1 919 745 2745
[email protected]
Press/Media Contact:
Danielle DeForge
Senior Director, External Communications
+1 781 425 2624
[email protected]
